29 July 2015 – PLC would like to recognize Adapt Pharma and Lightlake Therapeutics, partners developing a naloxone-based nasal spray for opioid overdose reversal, on their recent NDA submission to the US FDA. PLC has worked with both Adapt and Lightlake on their US regulatory filings and submitted the NARCAN® (naloxone hydrochloride) nasal spray NDA
23 July 2014 – PLC congratulates Lightlake Therapeutics on for their recent IND filing for a naloxone-based opioid overdose reversal nasal spray. PLC has worked with Lightlake on their regulatory pathway strategy for approval of this drug product and filed the IND application behalf of Lightlake. Lightlake Therapeutics Inc. Files Investigational NDA For Naloxone Nasal